Quarterly report pursuant to Section 13 or 15(d)

11. SEGMENTS

v3.8.0.1
11. SEGMENTS
 3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
11. SEGMENTS

The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company’s operating segments reflect the consummation of the Biotest Transaction on June 6, 2017 (see Notes 1 and 3), and the nature of its operations subsequent to the close of the transaction. The Company’s ADMA BioManufacturing segment reflects the Company’s immune globulin manufacturing and development operations in Florida, acquired on June 6, 2017 (see Note 3). The Plasma Collection Centers segment consists of two FDA-licensed source plasma collection facilities located in Georgia, with a third collection center which opened in December 2017 and for which an FDA license in pending. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:

 

Three Months Ended March 31, 2018
    ADMA BioManufacturing   Plasma Collection Centers   Corporate   Consolidated
                 
Revenues   $ 1,666,243     $ 2,340,055     $ 35,708     $ 4,042,006  
                                 
Cost of product revenue     10,697,642       1,545,106       —       12,242,748  
                                 
Loss from operations     (12,724,718 )     (1,038,824 )     (2,768,961 )     (16,532,503 )
                                 
Other expense, net     (240,054 )     (435 )     (1,049,150 )     (1,289,639 )
                                 
Net loss     (12,964,772 )     (1,039,259 )     (3,818,111 )     (17,822,142 )
                                 
Total assets     47,481,781       27,532,613       16,123,231       91,137,625  
                                 
Depreciation and amortization expense     631,832       188,914       8,795       829,541  
                                 
Capital expenditures     105,199       444,047       —       549,246  

 

Three Months Ended March 31, 2017
    ADMA BioManufacturing   Plasma Collection Centers   Corporate   Consolidated
                 
Revenues   $ —     $ 2,593,163     $ 35,708     $ 2,628,871  
                                 
Cost of product revenue     —       1,616,287       —       1,616,287  
                                 
Loss from operations     —       (502,600 )     (5,434,403 )     (5,937,003 )
                                 
Other expense, net     —       —       (599,960 )     (599,960 )
                                 
Net loss     —       (502,600 )     (6,034,363 )     (6,536,963 )
                                 
Total assets     —       2,286,500       15,308,418       17,594,918  
                                 
Depreciation and amortization expense     —       103,640       14,422       118,062  
                                 
Capital expenditures     —       2,084       1,500       3,584